Baxter International (NYSE:BAX) Price Target Raised to $25.00

Baxter International (NYSE:BAX) had its target price boosted by UBS Group from $19.00 to $25.00 in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a hold rating on the medical instruments supplier’s stock.

Other research analysts have also issued research reports about the stock. Weiss Ratings raised shares of Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. TD Cowen increased their target price on Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a research note on Monday. Evercore dropped their price target on Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Stifel Nicolaus increased their price objective on Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Zacks Research lowered shares of Baxter International from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Two research analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $21.09.

Baxter International Stock Performance

BAX opened at $26.65 on Tuesday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.23 and a current ratio of 1.85. The company has a market cap of $13.76 billion, a PE ratio of -12.51, a price-to-earnings-growth ratio of 4.00 and a beta of 0.62. The stock has a 50-day moving average of $21.20 and a 200-day moving average of $19.56. Baxter International has a 52-week low of $15.73 and a 52-week high of $30.00.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $2.80 billion. During the same period in the previous year, the company earned $0.59 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities research analysts forecast that Baxter International will post 1.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Baxter International

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of Baxter International by 98.3% during the 2nd quarter. GAMMA Investing LLC now owns 33,909 shares of the medical instruments supplier’s stock valued at $723,000 after acquiring an additional 16,809 shares in the last quarter. Versant Capital Management Inc lifted its stake in Baxter International by 552.2% during the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,043 shares during the period. Pacer Advisors Inc. boosted its holdings in Baxter International by 3.2% during the first quarter. Pacer Advisors Inc. now owns 41,709 shares of the medical instruments supplier’s stock valued at $701,000 after purchasing an additional 1,295 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Baxter International by 35.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 6,720 shares of the medical instruments supplier’s stock valued at $113,000 after purchasing an additional 1,763 shares during the period. Finally, Gabelli Funds LLC raised its holdings in shares of Baxter International by 0.6% in the 1st quarter. Gabelli Funds LLC now owns 498,000 shares of the medical instruments supplier’s stock worth $8,366,000 after buying an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Quarterly results exceeded expectations. Baxter reported second-quarter EPS of $0.56, ahead of the $0.36-$0.37 consensus range, while revenue rose 5.3% year over year to $2.96 billion versus estimates near $2.80 billion. Growth was broad-based across the company’s operating segments. Baxter Reports Second-Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 forecast. Full-year adjusted EPS guidance was increased to $1.95-$2.15 from the prior $1.85-$2.05 range, above the approximately $1.92 analyst consensus. Revenue guidance of $11.6-$11.7 billion also exceeded expectations near $11.4 billion. Baxter raises annual profit forecast on strong demand for IV solutions
• Positive Sentiment: Demand and operational momentum improved. Strong sales of IV solutions and drug-compounding products helped drive the beat. Baxter also received a tariff refund that provided an additional benefit not included in its earlier guidance, reinforcing the company’s turnaround narrative. Baxter raises annual profit forecast on strength in drug compounding business
• Neutral Sentiment: Analyst support improved, but valuation expectations remain mixed. UBS raised its price target to $25, while recent targets have ranged from $17 to $27. This suggests increased confidence in the recovery but also uncertainty about how much of the improvement is sustainable.
• Negative Sentiment: Profitability remains a concern. Adjusted earnings declined from the year-ago period, and analysts noted contracting margins due to tariffs, inflation and manufacturing costs. The tariff refund may also represent a one-time benefit rather than recurring earnings growth. BAX Stock Gains on Q2 Earnings and Sales Beat, Margins Contract
• Negative Sentiment: A reported antibiotic recall could add product-quality and execution risk. Investors may monitor whether the issue leads to broader recalls, supply disruption or additional costs.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.